Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS, INC. (REGN), sold 17,493 shares at $570.28 ($9.9M) on 2020-05-11, disclosed to the SEC on 2020-05-11.
Open-market sale of $9.9M REGN by EVP Research and Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $560.67 | 7,195 | $4.0M | 40.7% |
| 2 | $567.50 | 312 | $177K | 1.8% |
| 3 | $568.71 | 792 | $450K | 4.5% |
| 4 | $568.71 | 792 | $450K | 4.5% |
| 5 | $569.39 | 2,175 | $1.2M | 12.5% |
| 6 | $569.39 | 2,175 |
| $1.2M |
| 12.5% |
| 7 | $570.28 | 2,026 | $1.2M | 11.7% |
| 8 | $570.28 | 2,026 | $1.2M | 11.7% |
| Total | $565.91 avg | 17,493 | $9.9M | 100% |
| Filing → |
| REGN | SELL | 2023-08-23 | $19.6M | — | Filing → |
| REGN | SELL | 2022-08-08 | $28.4M | — | Filing → |
| REGN | SELL | 2021-05-18 | $18.2M | — | Filing → |